Summary
The purpose of this study was to investigate the toxicologic responses of mice to vincristine (VCR), an established antitumor drug, and to compare them with those reported for dogs, monkeys, and humans. This comparison was expected to facilitate the continuing appraisal of the mouse as a model for toxicologic responses to antitumor drugs in human patients. In duplicate experiments, male B6D2F1 mice were treated with 1.0, 1.5, 2.0, and 3.0 mg/kg of VCR in single IP doses. These sublethal doses corresponded to 0.25, 0.40, 0.50, and 0.80 LD50. On posttreatment days 1, 3, 6, 10, 14, and 21, groups of mice were killed and blood and other tissues were collected for hematologic (8 tests), clinical chemical (15 tests), and histopathologic (11 tissues) evaluations. VCR produced dose-dependent body weight loss, reticulocytopenia, granulocytopenia, elevated plasma alkaline phosphatase, GPT, and GOT activities, and damage to the gastrointestinal epithelium. These reversible changes were most severe during the first 3 days posttreatment. The mouse was comparable to the dog and the monkey in reflecting the target organ toxicity of VCR in humans. Studies with additional antitumor drugs will be required before the overall predictive reliability of this model can be expressed quantitatively.
Similar content being viewed by others
References
Adamson RH, Dixon RL, Ben M, Crews L, Shohet SB, Rall DP (1965) Some pharmacologic properties of vincristine. Arch Int Pharmacodyn 157: 299
Cancer Letter (1979) Editorial. 5
Cancer Letter (1982) Editorial. 4
Carpentieri U, Lockart LH (1978) Ataxia and athetosis as side effects of chemotherapy with vincristine in non-Hodgkin's lymphoma. Cancer Treat Rep 62: 561
Costa G, Hreshchyshyn MM, Holland JF (1962) Initial clinical studies with vinristine. Cancer Chemother Rep 24: 39
Folk RM, Peters AC, Pavkov KL, Swenberg JA (1974) Vincristine (NSC-67574): a retrospective toxicologic evaluation in monkeys and dogs using weekly intravenous injections for 6 weeks. Cancer Chemother Rep 5: 17
Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219
Harrison SD Jr (1981) Toxicologic evaluation of cis-diamminedichloroplatinum II in B6D2F1 mice. Fundamentals of Applied Toxicology 1: 382
Harrison SD Jr (1982) Variable host response to cytotoxic drugs: lethality, lesions and lessons. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand Reinhold, New York, p 136
Harrison SD Jr, Burdeshaw JA, Crosby RG, Cusic AM, Denine EP (1978) Hematology and clinical chemistry reference values for C57BL/6 x DBA/2F1 mice. Cancer Res 38: 2636
Harrison SD JR, Giles HD, Denine EP (1980) Antitumor drug toxicity in tumor-free and tumor-bearing mice. Cancer Chemother Pharmacol 4: 199
Prieur DJ, Young DM, Davis RD, Cooney DA, Homan ER, Dixon RL, Guarino AM (1973) Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the Laboratory of Toxicology. Cancer Chemother Rep 4: 1
Sethi VS, Kimball JC (1981) Pharmacokinetics of vincristine sulfate in children. Cancer Chemother Pharmacol 6: 111
Sethi VS, Jackson DV Jr, White DR, Richards F II, Stuart JJ, Muss HB, Cooper MR, Spurr CL (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41: 3551
Smart CR, Ottoman RE, Rochlin DB, Hornes J, Silva AR, Goepfert H (1968) Clinical experience with vincristine (NSC-67574) in tumors of the central nervous system and other malignant diseases. Cancer Chemother Rep 52: 733
Uy QL, Moen TH, Johns RJ, Owens AH Jr (1967) Vincristine neurotoxicity in rodents. Johns Hopkins Med J 121: 349
Weber W, Nagel GA, Nagel-Studer E, Albrecht R (1979) Vincristine infusion. A phase I study. Cancer Chemother Pharmacol 3: 49
Whitelaw DM, Cowan DH, Cassidy FR, Patterson TA (1963) Clinical experience with vincristine. Cancer Chemother Rep 30: 13
Wolf PL (1978) Clinical significance of an increased or decreased serum alkaline phosphatase level. Arch Pathol Lab Med 102: 497
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harrison, S.D. An investigation of the mouse as a model for vincristine toxicity. Cancer Chemother. Pharmacol. 11, 62–65 (1983). https://doi.org/10.1007/BF00257421
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257421